Melanoma | Clinical

OS Prolonged With I/O Before Targeted Therapy in Advanced BRAF-Mutant Melanoma

November 17, 2021

During the November 2021 Session of the American Society of Clinical Oncology Plenary Series, Michael B. Atkins, MD, presented data from the DREAMseq study, which compared 2 treatment sequences for advanced BRAF-mutant melanoma.

Alrizomadlin Lands FDA Fast Track Designation for Melanoma

September 23, 2021

Alrizomadlin, a MDM2-p53 inhibitor has been granted a fast track designation by the FDA for the treatment of relapsed/refractory unresectable or metastatic melanoma who are relapsed or refractory to prior immune-oncologic agents.

TFI and PFS2 in Frontline Advanced Melanoma Improved With Relatlimab/Nivolumab

September 18, 2021

In previously untreated patients with metastatic or unresectable melanoma, the addition of relatlimab to nivolumab prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone.